The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > MHLW Expert Panel on Comprehensive Policies
MHLW Expert Panel on Comprehensive Policies
-
Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
June 7, 2023
-
Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
-
Expert Panel Wants to See Action on Excessive Yakkasa, No Direction on Buffer Zone: Draft Report
June 5, 2023
-
Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
-
Outline of Expert Panel Report Calls for New Forum to Discuss Generics’ Future, Revisiting of Spillover Rule
April 28, 2023
-
Expert Panel Questions Requirement for Generic Listing in All Versions
April 5, 2023
-
Expert Panel Mixed on Macroeconomic Indexing of Drug Cost; Govt Urged to Quit Targeting Pharma for Savings
April 5, 2023
-
Expert Panel Discusses 2% Buffer Zone, Member Floats “Regional Index”
March 20, 2023
-
Expert Panel Seeks Revision of Drug Pricing Rules to Stabilize Supplies
March 20, 2023
-
Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
March 20, 2023
-
Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
February 16, 2023
-
5-Year Mandatory Stable Supply Rule for Generics under Scrutiny: Expert Panel
February 16, 2023
-
Experts Doubt Necessity of Policy Intervention for LLP-Dependent Companies
January 27, 2023
-
Expert Panel Member Alarmed by Stagnation of Biosimilar Business in Japan
January 27, 2023
-
Experts Call for Deregulations for Orphan Support, English Dossiers to Foster Biotech Ecosystem
January 16, 2023
-
Add New Evaluation Elements in Granting Launch Premiums: Expert Panel
December 12, 2022
-
Market Expansion Re-Pricing Has Gone Overboard with Spillover Rule, Experts Say
December 12, 2022
-
Revisit PMP Company Criteria to Support Innovation from Foreign Biotechs: Experts
December 12, 2022
-
Experts Call for New Drug Pricing Rule for Innovative Medicines, No Objections Raised
December 12, 2022
-
Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…